comparemela.com

Latest Breaking News On - Karyopharm therapeutics inc stock exchange - Page 1 : comparemela.com

Karyopharm Therapeutics : Corporate Presentation June 2023

Commercial-StagePharmaceutical Company Pioneering Novel Cancer Therapies June 2023 Forward-looking. | June 6, 2023

Karyopharm therapeutics incExchange commissionDrug administrationForward looking statementsPrivate securities litigation reform actQuarterly reportKaryopharm therapeuticsKaryopharm therapeutics inc stock exchangePress releaseUne kpti us48576u1060

Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NEWTON, Mass., June 1, 2023 /PRNewswire/ Karyopharm Therapeutics Inc. , a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company granted an. | June 1, 2023

United kingdomPrnewswire karyopharm therapeutics incKaryopharm therapeutics incSelective inhibitor of nuclear exportStock incentive planNasdaq listing ruleSelective inhibitorNuclear exportKaryopharm therapeuticsKaryopharm therapeutics inc stock exchangePress releaseRanted kpti us48576u1060

Karyopharm Announces Presentation of Interim Data from Phase 2 Study of Single-Agent Eltanexor in Relapsed/Refractory (R/R) Higher-Risk Myelodysplastic Neoplasms (MDS) at 17th International Congress on MDS

– Relapsed/Refractory MDS Patients Achieved Median Overall Survival of 8.7 months – – Historically, Median Overall Survival in this Hard to Treat Patient Population is Only. | May 3, 2023

United statesUnited kingdomReshma rangwalaSelective inhibitor of nuclear exportPrnewswire karyopharm therapeutics incDrug administrationInternational congress on myelodysplastic syndromesKaryopharm therapeutics incExchange commissionAchieved median overall survivalMedian overall survivalTreat patient populationResults indicate potential single agent activityInternational congressMyelodysplastic syndromesChief medical officer

Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NEWTON, Mass., May 1, 2023 /PRNewswire/ Karyopharm Therapeutics Inc. , a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company granted an. | May 1, 2023

United kingdomAmama sadiqKaryopharm therapeutics incSelective inhibitor of nuclear exportPrnewswire karyopharm therapeutics incScientific affairsSenior vice presidentGlobal medicalStock incentive planNasdaq listing ruleSelective inhibitorNuclear exportKaryopharm therapeuticsKaryopharm therapeutics inc stock exchangePress releaseRanted kpti us48576u1060

Karyopharm Therapeutics : April 11, 2023

NOTICE OF ANNUAL MEETING OF STOCKHOLDERS TO BE HELD ON WEDNESDAY, MAY 24, 2023 Dear Stockholder: You are cordially invited to our 2023. | April 11, 2023

United statesRichard paulsonMansoor raza mirzaBarrye greeneChristyj oligerAudit committee of the board directorsExchange commissionErnst youngCompensation committee interlocksKaryopharm therapeutics incCompensation committeeService on other company boardsKaryopharm therapeuticsIncentive planStock purchase planRestated certificate

vimarsana © 2020. All Rights Reserved.